Alumis Inc. (ALMS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$450.31M

Year ended 2025-12-31

-$455.47M

Trailing 12 months to 2026-06-30

2023-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$450.31M	n/m	2026-03-19, From 2025-01-01
2024-12-31	-$297.60M	n/m	2026-03-19, From 2024-01-01
2023-12-31	-$156.89M	n/a	2025-03-19, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Alumis Inc. (ALMS)	2025-12-31	-$450.31M	n/m
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	-$225.46M	n/m
Celularity Inc (CELU)	2025-12-31	-$54.01M	n/m
Cue Biopharma, Inc. (CUE)	2025-12-31	-$25.59M	n/m
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	-$43.81M	n/m
Scynexis Inc (SCYX)	2024-12-31	-$37.12M	n/m
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	-$7.43M	n/m
Foghorn Therapeutics Inc. (FHTX)	2025-12-31	-$83.06M	n/m
Bioharvest Sciences Inc. (BHST)	2025-12-31	-$3.95M	n/m

Compare ALMS, NAMS, CELU, CUE side by side · Screen every company in Pharmaceutical Preparations ↗